Lexaria Bioscience Corp. (LEXX)
|Net Income (ttm)||-3.72M|
|Trading Day||February 26|
|Day's Range||5.79 - 6.08|
|52-Week Range||3.98 - 9.46|
Lexaria Bioscience expands DehydraTECH CBD hypertension program with two new human trials; updates for others
Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) is expanding its applied research and development (R&D) program in 2021 with a particular focus on DehydraTECH-enabled CBD for hypertension, the...
New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital - Chris Bunka is a happy man. As CEO of Lexaria Bioscience (NASDAQ: LEXX) since 2006, he's battled to legitimize cannabino...
Lexaria Bioscience Corp. Discusses $11 Million Public Offering and 2021 Goals with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 28, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) ("the Company"), a company with the proprietary drug d...
KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is plea...
Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants
KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced the closing of its previously announced underwritten...
Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering
KELOWNA, BC / ACCESSWIRE / January 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced that its common stock and warrants will begin tradin...
Lexaria Bioscience operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.
Christopher A. Bunka
|Stock Exchange |
|Ticker Symbol |
In 2020, LEXX's revenue was $384,543, an increase of 72.74% compared to the previous year's $222,610. Losses were -$4.08 million, -1.77% less than in 2019.